Clinical trials: Capecitabine
Rectal Cancer
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Patients diagnosed with locally advanced very low rectal cancer were chosen to participate in a comprehensive neoadjuvant therapy (TNT) protocol.
- Trial name
- TRACE-LE (NCT05969847)
- Testing
- split-course hypofraction radiotherapy, CAPOX, Envafolimab
- Where
- China
- Volunteers
- 72 people
- Sponsor
- 池畔
Pancreatic Cancer
NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer
This is an open label, randomized phase 2 study of NaliCap (irinotecan liposome/Capecitabine) compared to NAPOLI (irinotecan liposome/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer patients.
- Trial name
- NaliCap (NCT04371224)
- Testing
- Irinotecan Liposomal Injection [Onivyde], Capecitabine, 5-fluorouracil
- Where
- 2 sites in South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Colorectal Cancer, RAS Mutation
PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC
This study is designed to explore the efficacy and safety of anti-PD-1 antibody plus bevacizumab and chemotherapy as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer.
- Conditions
- Colorectal Cancer, RAS Mutation, Colorectal Neoplasms, Microsatellite Stable Colorectal Carcinoma
- Trial name
- NCT06206096
- Testing
- oxaliplatin+capecitabine+bevacizumab+PD-1 antibody
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese PLA General Hospital
Esophageal Malignant Neoplasm, Local Recurrence
Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence
Esophageal cancer is still a serious threat to human life and health. China in particular. Relapse and metastasis are important causes of treatment failure.
- Trial name
- NCT04404491
- Testing
- Procedural death 1, Capecitabine, Radiotherapy
- Volunteers
- 240 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Metastatic Breast Cancer
Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study
Women with recurrent or metastatic breast cancer who are hormone receptor positive are candidates for first line hormonal therapy including aromatase inhibitors.
- Trial name
- CONCEPT (NCT04012918)
- Testing
- Capecitabine plus aromatase inhibitor, A.I.
- Where
- Egypt
- Volunteers
- 124 people
- Sponsor
- Ain Shams University
Colorectal Cancer Stage IV
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Sintilimab (R\&D code: IBI308) is a recombinant human-derived IgG4 type PD-1 monoclonal antibody. PD-1 inhibitor combined with chemotherapy has synergistic effect to further enhance anti-tumor immunity.
- Trial name
- NCT05171660
- Testing
- Sintilimab, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Rectal Cancer, Prognosis
Prognostic Value of Neutrophil-to-lymphocyte Ratio (NLR) on Rectal Cancer Patients
We explored the relationship between NLR and grade 3 or higher treatment related small bowel toxicity and treatment outcome of patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy…
- Trial name
- NCT03015168
- Testing
- capecitabine and concurrent intensity modulated radiotherapy
- Where
- China
- Volunteers
- 117 people
- Sponsor
- General Hospital of Ningxia Medical University
Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the…
- Conditions
- Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02595424
- Testing
- Capecitabine, Carboplatin, Cisplatin
- Where
- 673 sites in United States
- Volunteers
- 67 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Biliary Tract Cancer, Extrahepatic Cholangiocarcinoma
Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer
The study is a multicenter phase II randomized controlled trial. The purpose is to investigate the efficacy and safety of adjuvant immunotherapy combined with chemoradiation for patients with high-risk resectable extrahepatic…
- Conditions
- Biliary Tract Cancer, Extrahepatic Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- ACCORD (NCT04333927)
- Testing
- Chemotherapy, Observation, Immunotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Sun Yat-sen University
Pancreatic Neoplasms, Pancreatic Cancer
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
The purpose of this study is to evaluate optimal dose and safety of the combination of Abraxane, gemcitabine, and Xeloda (capecitabine) (AGX) as first-line therapy in patients with metastatic pancreatic cancer.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer, Adenocarcinoma
- Trial name
- NCT01161186
- Testing
- nab-paclitaxel, gemcitabine, capecitabine
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- Magic-C002 (NCT06976190)
- Testing
- MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Rectal Cancer
Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer
This prospective randomized, open-label, multicenter, phase II clinical trial investigates the safety and tolerability of standard neoadjuvant chemoradiotherapy (CRT) with sequential ipilimumab and nivolumab in rectal cancer.
- Trial name
- CHINOREC (NCT04124601)
- Testing
- Chemoradiotherapy, Ipilimumab, Nivolumab
- Where
- 5 sites in Austria
- Volunteers
- 80 people
- Sponsor
- Johannes Laengle, MD, PhD
Nasopharyngeal Carcinoma, Local Recurrence
MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
This study enrolls patients who have experienced local recurrence of nasopharyngeal carcinoma (NPC) with or without regional recurrence.
- Trial name
- NCT07331428
- Testing
- MRG003, Tislelizumab, Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fujian Cancer Hospital
Colorectal Cancer
Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer
The purpose of this study is to investigate whether chemotherapy guided by patient-derived tumor organoid drug test can improve the outcomes of stage IV colorectal cancer.
- Trial name
- NCT05832398
- Testing
- FOLFOX , FOLFIRI or FOLFOXIRI regimens, FOLFOX or CapeOX regimens
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nasopharyngeal Carcinoma
Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
To prospectively evaluate the short-term efficacy and toxicity of induction chemotherapy with cisplatin and capecitabine followed by concurrent chemoradiotherapy (CCRT) in the treatment of locally advanced nasopharyngeal…
- Trial name
- NCT03427359
- Testing
- cisplatin, capecitabine
- Volunteers
- 65 people
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
HER 2 Positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
The study will have a dose escalation part (Phase 1b) and a randomized part (Phase 2). In Phase 1b, patients diagnosed with advanced HER2 positive gastric/gastroesophageal adenocarcinoma will be enrolled in a 3 + 3 design dose…
- Trial name
- NCT07040059
- Testing
- AUR103 Calcium, Trastuzumab + CAPOX (Capecitabine + Oxaliplatin)
- Where
- 8 sites in India
- Volunteers
- 2 people
- Sponsor
- Aurigene Discovery Technologies Limited
Vitamin D3
XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC
The study is a randomized,multicenter, double-blinded,phase III study. To explore the affection of vitamin D3 in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine as first-line…
- Trial name
- NCT03389659
- Testing
- vitamin D3
- Volunteers
- 750 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer, Metastatic Breast Cancer
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
In 2008 there were more than 40,000 deaths caused by metastatic breast cancer in the United States. The development of new treatment strategies is essential to improve outcome for patients with metastatic breast cancer There is…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01349088
- Testing
- Ixabepilone, Capecitabine, Motesanib
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Gastric Cancer
Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis
Gastric cancer with retroperitoneal lymph node metastasis was considered as unresectable, to improve these patients' prognosis, we designed systematic conversion therapy including immunotherapy and chemoradiotherapy.
- Trial name
- NCT05002686
- Testing
- Sintilimab, Albumin-Paclitaxel, Capecitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00486356
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska